SG11202100518TA - A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis - Google Patents
A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosisInfo
- Publication number
- SG11202100518TA SG11202100518TA SG11202100518TA SG11202100518TA SG11202100518TA SG 11202100518T A SG11202100518T A SG 11202100518TA SG 11202100518T A SG11202100518T A SG 11202100518TA SG 11202100518T A SG11202100518T A SG 11202100518TA SG 11202100518T A SG11202100518T A SG 11202100518TA
- Authority
- SG
- Singapore
- Prior art keywords
- prevention
- treatment
- multiple sclerosis
- substituted amino
- pyrimidine compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700977P | 2018-07-20 | 2018-07-20 | |
| US201862730184P | 2018-09-12 | 2018-09-12 | |
| US201962839273P | 2019-04-26 | 2019-04-26 | |
| PCT/IB2019/056198 WO2020016850A1 (en) | 2018-07-20 | 2019-07-19 | A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100518TA true SG11202100518TA (en) | 2021-02-25 |
Family
ID=67953828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100518TA SG11202100518TA (en) | 2018-07-20 | 2019-07-19 | A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210260060A1 (ja) |
| EP (1) | EP3823623A1 (ja) |
| JP (1) | JP2021532104A (ja) |
| KR (1) | KR20210034623A (ja) |
| CN (1) | CN112437665A (ja) |
| AU (1) | AU2019306828A1 (ja) |
| BR (1) | BR112021000893A2 (ja) |
| CA (1) | CA3106772A1 (ja) |
| IL (1) | IL280197A (ja) |
| MX (1) | MX2021000094A (ja) |
| SG (1) | SG11202100518TA (ja) |
| TW (1) | TW202019425A (ja) |
| UA (1) | UA127744C2 (ja) |
| WO (1) | WO2020016850A1 (ja) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3217452A1 (en) | 2021-05-14 | 2022-11-17 | David Andrew Coates | Cocrystalline forms of a bruton's tyrosine kinase inhibitor |
| WO2023285696A1 (en) * | 2021-07-15 | 2023-01-19 | Sandoz Ag | Mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one |
| WO2023247774A1 (en) | 2022-06-24 | 2023-12-28 | Merck Patent Gmbh | Treatment regimen for autoimmune diseases and inflammatory diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10060388A1 (de) * | 2000-12-05 | 2002-06-06 | Merck Patent Gmbh | Verwendung von Pyrazolo [4,3-d]pyrimidinen |
| WO2011156900A2 (en) * | 2010-06-17 | 2011-12-22 | Waratah Pharmaceuticals Inc. | Compounds, compositions and methods for treatment of multiple sclerosis |
| JP2014517016A (ja) * | 2011-06-10 | 2014-07-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋ阻害活性を有するピリミジンおよびピリミジン化合物の組成物と製造方法 |
| AU2013207972B2 (en) * | 2012-01-10 | 2017-06-15 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
| TW201347762A (zh) * | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途 |
| BR112018007517B1 (pt) | 2015-11-17 | 2023-09-26 | Merck Patent Gmbh | Uso decompostos de pirimidina e piridina com atividade inibidora de btk para preparar medicamentos para tratar esclerose múltipla |
| US10464923B2 (en) * | 2017-02-27 | 2019-11-05 | Merck Patent Gmbh | Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone |
-
2019
- 2019-07-19 TW TW108125526A patent/TW202019425A/zh unknown
- 2019-07-19 KR KR1020217004655A patent/KR20210034623A/ko unknown
- 2019-07-19 CA CA3106772A patent/CA3106772A1/en active Pending
- 2019-07-19 EP EP19768898.9A patent/EP3823623A1/en active Pending
- 2019-07-19 BR BR112021000893-4A patent/BR112021000893A2/pt unknown
- 2019-07-19 MX MX2021000094A patent/MX2021000094A/es unknown
- 2019-07-19 CN CN201980048404.9A patent/CN112437665A/zh active Pending
- 2019-07-19 AU AU2019306828A patent/AU2019306828A1/en active Pending
- 2019-07-19 SG SG11202100518TA patent/SG11202100518TA/en unknown
- 2019-07-19 WO PCT/IB2019/056198 patent/WO2020016850A1/en unknown
- 2019-07-19 US US17/261,407 patent/US20210260060A1/en active Pending
- 2019-07-19 UA UAA202100604A patent/UA127744C2/uk unknown
- 2019-07-19 JP JP2021503059A patent/JP2021532104A/ja active Pending
-
2021
- 2021-01-14 IL IL280197A patent/IL280197A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021000094A (es) | 2021-03-25 |
| TW202019425A (zh) | 2020-06-01 |
| CA3106772A1 (en) | 2020-01-23 |
| US20210260060A1 (en) | 2021-08-26 |
| EP3823623A1 (en) | 2021-05-26 |
| IL280197A (en) | 2021-03-01 |
| UA127744C2 (uk) | 2023-12-20 |
| WO2020016850A1 (en) | 2020-01-23 |
| KR20210034623A (ko) | 2021-03-30 |
| CN112437665A (zh) | 2021-03-02 |
| BR112021000893A2 (pt) | 2021-04-13 |
| JP2021532104A (ja) | 2021-11-25 |
| AU2019306828A1 (en) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282487A (en) | TYK2 inhibitors and their use | |
| IL276095B1 (en) | gcn2 inhibitors and their uses | |
| IL276147A (en) | GCN2 inhibitors and uses thereof | |
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| IL275626A (en) | Preparations and methods for surface treatment | |
| IL282090A (en) | tyk2 inhibitors and uses thereof | |
| IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
| SG11202100518TA (en) | A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis | |
| IL283409A (en) | tyk2 inhibitors and uses thereof | |
| IL279347A (en) | Gremlin-1 antagonist for cancer prevention and treatment | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| PL3736382T3 (pl) | Jednostka zapobiegająca erozji i sposób zapobiegania erozji | |
| EP3983062A4 (en) | AESTHETIC TREATMENT SYSTEMS AND METHODS | |
| IL286697A (en) | Neurogulin-4 compounds and methods of use | |
| IL286149A (en) | Caspase inhibitors and methods of using them | |
| IL280348A (en) | Surface treatment compositions and methods | |
| IL276053A (en) | Therapeutic-gard and method of use thereof | |
| GB2573856B (en) | Dispenser system and method of use | |
| EP3595640A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| IL252424A0 (en) | Treatment of multiple sclerosis with a combination of laquinimod and a statin | |
| GB2589398B (en) | Compounds and methods of use | |
| IL269681A (en) | New methods for treating multiple sclerosis | |
| EP3924335A4 (en) | ANTI-FIBROTIC NEU3 INHIBITOR COMPOUNDS AND METHODS OF USE | |
| IL265976A (en) | Use of a compound, pharmaceutical preparation and therapeutic method for the treatment or prevention of convulsions | |
| IL259383A (en) | A compound for use in the prevention and treatment of neurodegenerative diseases |